Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV001254666 | SCV001809909 | likely pathogenic | Glanzmann thrombasthenia | 2022-08-05 | reviewed by expert panel | curation | The missense variant NM_000419.5(ITGA2B):c.2444A>G (p.Tyr815Cys) has been reported, in the homozygous state (PM3_supporting), in at least one GT proband (P15 in PMID: 34275420) who displayed mucocutaneous bleeding and impaired aggregation with all agonists except ristocetin, which is highly specific for Glanzmann thrombasthenia. Additionally, αIIbβ3 surface expression was reduced to <5%, as measured by flow cytometry (PP4_strong). The variant is absent from population cohorts, including gnomAD. In summary, this variant meets criteria to be classified as Likely Pathogenic for GT. GT-specific criteria applied: PM2_supporting, PM3_supporting, PP4_strong. |
Departement d'Immunology Plaquettaire, |
RCV001254666 | SCV001430686 | pathogenic | Glanzmann thrombasthenia | criteria provided, single submitter | provider interpretation | The variant impairs the expression of the platelets fibrinogen receptor alphaIIb beta3 |